Endothelial AMP-Activated Protein Kinase Regulates Blood Pressure and Coronary Flow Responses Through Hyperpolarization Mechanism in Mice

Budbazar Enkhjargal, Shigeo Godo, Ayuko Sawada, Nergui Suvd, Hiroki Saito, Kazuki Noda, Kimio Satoh, Hiroaki Shimokawa

**Objective**—Vascular endothelium plays an important role to maintain cardiovascular homeostasis through several mechanisms, including endothelium-dependent hyperpolarization (EDH). We have recently demonstrated that EDH is involved in endothelial metabolic regulation in mice. However, it remains to be examined whether AMP-activated protein kinase (AMPK), an important metabolic regulator, is involved in EDH and if so, whether endothelial AMPK (eAMPK) plays a role for circulatory regulation.

**Approach and Results**—We examined the role of eAMPK in EDH, using mice with endothelium-specific deficiency of α-catalytic subunit of AMPK, either αι (eAMPK\(\alpha_1^-\alpha_2^+\)) or αε (eAMPK\(\alpha_1^-\alpha_2^-\)) alone or both of them (eAMPK\(\alpha_1^-\alpha_2^+\)). We performed telemetry, organ chamber, electrophysiological, and Langendorff experiments to examine blood pressure, vascular responses, hyperpolarization of membrane potential, and coronary flow responses, respectively. Hypertension was noted throughout the day in eAMPK\(\alpha_1^-\alpha_2^+\) and eAMPK\(\alpha_1^-\alpha_2^-\) but not in eAMPK\(\alpha_1^-\alpha_2^-\) mice when compared with respective control. Importantly, endothelium-dependent relaxations, EDH, and coronary flow increase were all significantly reduced in eAMPK\(\alpha_1^-\alpha_2^+\) and eAMPK\(\alpha_1^-\alpha_2^-\) but not in eAMPK\(\alpha_1^-\alpha_2^-\) mice. In contrast, endothelium-independent relaxations to sodium nitroprusside (a NO donor), NS-1619 (a Ca\(^++\)-activated K\(^+\) channel opener), and exogenous H\(_2\)O\(_2\) were almost comparable among the groups. In eAMPK\(\alpha_1^-\alpha_2^-\) mice, antihypertensive treatment with hydralazine or long-term treatment with metformin (a stimulator of AMPK) failed to restore EDH-mediated responses.

**Conclusions**—These results provide the first direct evidence that αι subunit of eAMPK substantially mediates EDH responses of microvessels and regulates blood pressure and coronary flow responses in mice in vivo, demonstrating the novel role of eAMPK in cardiovascular homeostasis. *(Arterioscler Thromb Vasc Biol. 2014;34:1505-1513.)*

**Key Words:** AMP-activated protein kinases • blood pressure • endothelial cells • endothelium-dependent hyperpolarization factor

Vascular endothelium regulates vascular tone by releasing endothelium-derived relaxing and contracting factors, including nitric oxide (NO), prostacyclin, endothelium-derived hyperpolarizing factor (EDHF), endothelin, and prostaglandin F\(_2\)\(_\alpha\), all of which regulate vascular homeostasis through multiple mechanisms. When compared with NO\(^1\) and prostacyclin,\(^2\) relatively little is known about the biochemical, physiological, and pharmacological aspects of endothelium-dependent hyperpolarization (EDH). However, EDHF is considered as one of the important endothelium-derived relaxing factors, especially in resistance arteries.\(^3,4\) During the past 25 years, experiments were performed to clarify the nature of EDHF, identifying several candidates, including K\(^+\) ion, arachidonic acid metabolites, electric gap communications, C-type natriuretic peptide, endogenous cannabinoid, ecto-5'-nucleotidase, and hydrogen sulfide.\(^5\) It is now widely accepted that multiple EDHFs may exist depending on blood vessels and species studied.\(^6-8\) We and others have previously identified that endothelium-derived H\(_2\)O\(_2\) is one of the major EDHFs in mouse mesenteric arteries,\(^9,10\) porcine coronary arteries,\(^11\) and human coronary and mesenteric arteries.\(^12-15\) Impaired EDH-type responses have been reported under various pathological conditions, including hypertension, atherosclerosis, hypercholesterolemia, heart failure, ischemia/reperfusion, and diabetes mellitus,\(^5,16\) indicating the important roles of EDH in the maintenance of cardiovascular homeostasis. Furthermore, we have recently demonstrated that endothelium-derived H\(_2\)O\(_2\) also plays an important role in endothelial metabolic regulation in mice.\(^17\)

Vascular endothelial dysfunction plays a critical role in the pathogenesis of metabolic syndrome, such as obesity, diabetes mellitus, and hypertension, all of which cause cardiovascular
complications, including myocardial infarction, stroke, and heart and renal failure.18 Recently, the role of AMP-activated protein kinase (AMPK) has attracted much attention as an important regulator of metabolic functions.19 AMPK consists of heterotrimeric complex with a catalytic subunit α and 2 regulatory subunits β and γ,20 each having α2 isoforms (α1, α2β1, β2, γ1, γ2, and γ3) that are differentially expressed in various tissues and subcellular locations.21 In the vascular endothelium, both α subunits of AMPK (α1 and α2) are expressed although AMPKα2 is expressed to a greater extent than AMPKα1.22 Previous studies have demonstrated that the predominant isoform expressed in vascular endothelial cells is α1.23,24 However, because most studies were performed using systemic knockout or transgenic mice to examine the role of AMPK, the specific role of endothelial AMPK (eAMPK) on endothelium-dependent responses remains to be examined.25

Endothelium-dependent vasodilatation is a vital mechanism of blood flow regulation in response to increased metabolic demand. As a metabolic sensor, eAMPK plays an important role in metabolic regulation of blood flow,24,26 which is also regulated by endothelial NO synthase (eNOS)27,28 through AMPK activation.29,30 However, the role of eAMPK in EDH remains to be elucidated. Thus, in the present study, we examined whether eAMPK is involved in EDH and if so, whether it plays a role in blood pressure regulation in mice.

Materials and Methods
Materials and Methods are available in the online-only Supplement.

Results
Characteristics of Endothelial-Specific AMPK-KO Mice
AMPK is ubiquitously detectable in all cells of organism. To examine the role of eAMPK selectively, we newly generated eAMPKα−/−α1−/−, eAMPKα−/−α2−/−, and eAMPKα−/−α1−/−α2−/− mice. We also newly generated each littermate, including controlα−/−α1−/−, controlα1−/−α2−/−, and controlα1−/−α2−/− mice, respectively, because genotype is different in each group. All mice were genotyped by polymerase chain reaction on tail clip samples (Figure IA in the online-only Data Supplement). We also confirmed endothelium-selective knockdown of AMPK isoforms in the aorta, mesenteric, and coronary arteries by immunofluorescence staining method as described in our previous study (Figure 1).27,31 Characteristics of mice, including body, organ, and fat weights and blood and lipid profiles, are shown in Table I in the online-only Data Supplement. Body weight was significantly decreased in eAMPKα−/−α1−/−α2−/− and eAMPKα−/−α1−/−α2−/− mice, but not in eAMPKα−/−α1−/−α2−/− mice, when compared with each littermate mice. Moreover, heart:body weight ratio was significantly increased in eAMPKα−/−α1−/−α2−/− and eAMPKα−/−α1−/−α2−/− mice, but not in eAMPKα−/−α1−/−α2−/− mice, when compared with each littermate mice, indicating that α1 is the dominant catalytic subunit of endothelial AMPK23,24,32 related to cardiac hypertrophy. Glucose tolerance was comparable between eAMPKα−/−α1−/−α2−/− and controlα1−/−α2−/− mice (Figure IB in the online-only Data Supplement). The weights of other organs and visceral fats were comparable between eAMPK-KO and control mice. This was also the case for blood and lipid profiles (Table I in the online-only Data Supplement).

Role of eAMPK in Blood Pressure Regulation
To study the role of eAMPK in blood pressure regulation in vivo, we monitored blood pressure of eAMPK-KO and control mice by telemetry in vivo. When compared with controls, mean, systolic, and diastolic arterial pressures were significantly higher in eAMPKα−/−α1−/−α2−/− and eAMPKα−/−α1−/−α2−/− mice throughout the day but remained unaltered in eAMPKα1−/−α2−/− mice (Figure 2; Figure II in the online-only Data Supplement), indicating that eAMPKα1 plays an important role in blood pressure regulation. In eAMPK-KO mice, heart rate was not
markedly reduced and the remaining relaxations were inhibited by L-NNA and indomethacin, indicating the compensatory roles of NO and prostacyclin (Figure 3A). Moreover, in mesenteric arteries of eAMPKα1−/−α2−/− mice, EDH-mediated relaxations were significantly impaired when compared with control,6α1+α2+ mice (Figure 3B), whereas the same extent of relaxations was noted in both eAMPKα1−/−α2−/− and control α1+α2+ mice (Figure 3C). In eAMPKα1−/−α2−/− mice, endothelium-independent relaxations to sodium nitroprusside (a NO donor) were rather significantly impaired but showed biphasic responses in mesenteric artery (Figure IX in the online-only Data Supplement), whereas NS-1619 (an opener of Ca2+-activated K+ channel) caused comparable extent of relaxations of the aorta and mesenteric arteries among all the groups (Figure X in the online-only Data Supplement). Furthermore, endothelium-independent relaxations to exogenous H2O2 were comparable among the groups (Figure XI in the online-only Data Supplement). Electrophysiological recordings of membrane potentials with the microelectrode technique in the vascular smooth muscle cell of mesenteric arteries demonstrated that EDH to acetylcholine were significantly reduced in eAMPKα1−/−α2−/− and eAMPKα1−/−α2−/− mice when compared with that in respective control mice in the presence of L-NNA and indomethacin (Figure 3D and 3E).

**Important Role of eAMPK in Coronary Flow Regulation**

Cardiac hypertrophy was noted in eAMPKα1−/−α2−/− and eAMPKα1−/−α2−/− mice but not in eAMPKα1−/−α2−/− mice (Figure 4A; Table I in the online-only Data Supplement). In the Langendorff experiments, baseline coronary flow was significantly increased in eAMPKα1−/−α2−/− and eAMPKα1−/−α2−/− mice when compared with each control littermates, suggesting the effects of cardiac hypertrophy in these mice (Figure 4B). Importantly, bradykinin-induced endothelium-dependent increases in coronary flow were significantly reduced in eAMPKα1−/−α2−/− and eAMPKα1−/−α2−/− mice, but not in eAMPKα1−/−α2−/− mice, when compared with each control littermates (Figure 4C–4E). In contrast, sodium nitroprusside-induced endothelium-independent responses were comparable between eAMPK-KO mice and controls (Figure 4).

**Hydralazine Failed to Restore EDH in eAMPKα1−/−α2−/− Mice**

eAMPKα1−/−α2−/− mice showed high blood pressure throughout the day. After 1-month treatment with hydralazine, blood pressure was significantly decreased in day time but not at night time (Figure IVA and IVB in the online-only Data Supplement), whereas heart rate was unchanged (Figure IVC in the online-only Data Supplement). Cardiac hypertrophy still remained in hydralazine-treated eAMPKα1−/−α2−/− mice (Figure IVD; Table II in the online-only Data Supplement). Although endothelium-dependent relaxations were significantly improved in mesenteric arteries (but not in the aorta) in hydralazine-treated eAMPKα1−/−α2−/− mice (Figure 5A), this was mainly caused by NO and prostacyclin (Figure VII in the online-only Data Supplement). Hydralazine had no effects on endothelium-independent relaxations to NS-1619 or

**eAMPK Regulates EDH Responses**

In the organ chamber experiments, we used isolated aorta and mesenteric arteries, which can contract in response to 60 mmol/L of KCl (Figure V in the online-only Data Supplement). In the aorta, acetylcholine-induced endothelium-dependent relaxations were comparable among all eAMPK-KO and control mice, and the responses were inhibited by NO-nitroarginine (L-NNA; 100 μmol/L, an inhibitor of NOS) and indomethacin (10 μmol/L, an inhibitor of cyclooxygenase; Figure VI in the online-only Data Supplement). However, in mesenteric arteries of control,6α1+α2+ mice, acetylcholine-induced endothelium-dependent relaxations were resistant to L-NNA and indomethacin but were highly sensitive to the combination of apamin and charybdotoxin in the presence of L-NNA and indomethacin, a consistent finding with EDH-mediated relaxations.9,10,17,33 In contrast, in mesenteric arteries of eAMPKα1−/−α2−/− mice, EDH-mediated relaxations to acetylcholine were significantly increased in all groups (Figure III in the online-only Data Supplement). Thus, the present results indicate that eAMPKα1 is the dominant catalytic subunit of AMPK in blood pressure regulation.

**Figure 2. Elevated blood pressure (BP) in eAMPKα1−/−α2−/− and eAMPKα1−/−α2−/− mice.** Telemetric BP monitoring in (A) eAMPKα1−/−α2−/− vs control,6α1+α2+ (n=5–6 each). Data are presented as mean arterial pressure (MAP) during 24-hour recording (left) and time averaged systolic and diastolic BP (right). Results are expressed as meansSEM. *P<0.05 vs control. AMPK indicates AMP-activated protein kinase.
Figure 3. Impaired endothelium-dependent relaxations of mesenteric arteries from endothelial AMP-activated protein kinase knockout (eAMPK-KO) mice. Endothelium-dependent responses to acetylcholine (ACh) in (A) eAMPKα\textsubscript{1}−/−α\textsubscript{2}−/− vs control α\textsubscript{1}f/fα\textsubscript{2}f/f, (B) eAMPKα\textsubscript{1}−/−α\textsubscript{2}+/− vs control α\textsubscript{1}f/fα\textsubscript{2}f/f, and (C) eAMPKα\textsubscript{1}+/−α\textsubscript{2}−/− vs control α\textsubscript{1}f/fα\textsubscript{2}f/f mice (n=7–10 each) in the absence (○) and the presence of indomethacin (□), Indo, Indo plus N\textsubscript{ω}-nitro-L-arginine (∆, L-NNA), and Indo, L-NNA plus charybdotoxin and apamin (lozenge). Data are presented as dose-dependent responses (left) and area under the curve (right). Representative traces (left) of resting membrane potentials and ACh-induced hyperpolarizations in (D) eAMPKα\textsubscript{1}−/−α\textsubscript{2}−/− vs control α\textsubscript{1}f/fα\textsubscript{2}f/f and (E) eAMPKα\textsubscript{1}−/−α\textsubscript{2}−/− vs control α\textsubscript{1}f/fα\textsubscript{2}f/f and quantitative results of EDH (right; n=7–10 in each). Results are expressed as mean±SEM. **P<0.01; ***P<0.001 vs control. EDH indicates endothelium-dependent hyperpolarization; NO, nitric oxide; and PGI\textsubscript{2}, prostacyclin.
The improvement was mainly mediated by NO and prostacyclin in resistance arteries but not those of the aorta (Figure 5B).

**Metformin Failed to Restore EDH in eAMPKα1−/−α2−/− Mice**

After 1-month treatment with metformin, blood pressure was significantly decreased during day time but not during night time (Figure IVA in the online-only Data Supplement), whereas heart rate was unchanged (Figure IVC in the online-only Data Supplement). Cardiac hypertrophy still remained in metformin-treated eAMPKα1−/−α2−/− mice (Figure IVD; Table II in the online-only Data Supplement). In eAMPKα1−/−α2−/− mice, 1-month treatment with metformin significantly improved endothelium-dependent relaxations of mesenteric arteries but not those of the aorta (Figure 5B). The improvement was mainly mediated by NO and prostacyclin (Figure VIII in the online-only Data Supplement).

Metformin had no effects on endothelium-independent relaxations to NS-1619 or exogenous H2O2 in control and eAMPKα1−/−α2−/− mice (Figure XIII in the online-only Data Supplement).

**Discussion**

The novel finding of the present study with eAMPK-KO mice was that α1 subunit of eAMPK plays an important role in EDH responses in resistance arteries and blood pressure control in mice. Although NO and prostacyclin play some compensatory roles, the extent of the compensation was not enough to prevent blood pressure elevation. To the best of our knowledge, this is the first study that demonstrates that eAMPK plays an important role in regulating blood pressure and coronary flow responses through EDH mechanisms (Figure 6).
Endothelial AMPK Mediates EDH

EDH is mediated by multiple mechanisms involving endothelial and vascular smooth muscle cell components, and several candidates have been proposed as a nature of EDHF, including H2O2.3,6,7,9,34 Recently, Prysyazhna et al.15 showed that dimerization of protein kinase G 1α plays an important role in H2O2-mediated vascular smooth muscle cell relaxation, which finding was subsequently confirmed in the human coronary artery.35 We have also previously demonstrated that the 3 NOS isoforms in the endothelium are important sources of H2O2 as an EDHF,3,9,10 and endothelial Cu,Zn-SOD plays an important role as an EDHF synthase,36 and recently summarized in our findings related to these issues.37 Interestingly, AMPK is the only kinase that can phosphorylate eNOS on ≥1 site, including Ser117730 and Ser63329 as activating sites in the reductase domain and Thr495 as an inhibitory site in the calmodulin-binding domain.38,39 Recently, we have demonstrated that eNOS is functionally inhibited under physiological conditions through reduced phosphorylation at Ser1177 and increased phosphorylation at Thr495.33 In the present study, we were able to demonstrate that endothelial AMPKα1 substantially mediates EDH in mouse resistance arteries (eg, mesenteric and coronary arteries) but not in the aorta. eNOS is activated in a Ca2+-dependent manner,40 and NO itself acts as an endogenous activator of AMPK in a Ca2+-dependent manner, involving CaMKKβ.41 An increase in endothelial Ca2+, crucial step in EDH mechanism,34,39 activates Ca2+/CaM-dependent protein kinase β with resultant AMPK activation.42 H2O2 could activate endothelial AMPK through Ca2+/CaM-dependent protein kinase β pathway within its physiological concentrations, which could be a possible important feedback mediator of AMPK.43 In the present study, we found that vascular smooth muscle cell hyperpolarization of mesenteric arteries (in the presence of NO and prostacyclin inhibitors) was significantly impaired in eAMPK-KO mice with reduced relaxation responses, indicating that eAMPK is substantially involved in EDH responses.44

Figure 5. Hydralazine and metformin failed to restore endothelium-dependent hyperpolarization (EDH). Effects of hydralazine (A) and metformin (B) treatment in the acetylcholine (ACH)–induced EDH-type responses of the aorta and mesenteric arteries (MA), comparing eAMPKα1α2−/− mice and eAMPKα1α2−/− plus metformin mice vs eAMPKα1α2−/− mice (n=6–7 each) in the absence (○) and the presence of indomethacin (Indo) plus Nω-nitro-l-arginine (L-NNA; ∆). Data are presented as dose-dependent responses (left) and area under the curve (right). Results are expressed as means±SEM. *P<0.05; **P<0.01 vs eAMPKα1α2−/− mice. Although endothelium-dependent relaxations were significantly improved in MA (but not in the aorta) of eAMPKα1α2−/− mice by hydralazine and metformin, this was mainly caused by nitric oxide (NO) and prostacyclin because the improved responses were abolished by Indo and L-NNA. AMPK indicates AMP-activated protein kinase.
Mechanisms of eAMPK-Mediated EDH
Although no drug is currently available to improve EDH-mediated responses directly, beneficial indirect effects of several drugs on EDH-mediated responses have been reported, including angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers.5,45 Our previous study showed that EDH component was not restored by the antihypertensive treatment with hydralazine in eNOS-KO mice.9 In the present study, we found that hydralazine failed to restore EDH-dependent relaxations in mesenteric arteries of eAMPKα1−/−α2−/− mice. These results indicate that the impaired EDH-mediated responses in eAMPKα1−/−α2−/− mice were not the results of elevated blood pressure but were directly related to eAMPK.

Nonpharmacological therapeutic strategies, including exercise and supplementation with estrogens, ω3-polyunsaturated fatty acids, and polyphenol derivatives have been reported to improve endothelial dysfunction with reduced EDH-mediated responses.5 Moreover, several pharmacological agents are known to activate AMPK, including glitazones and biguanides, by indirect pathways in whole organism.24 Metformin, a biguanide derivative, is one of the most commonly used drug for the treatment of type 2 diabetes mellitus.46 Despite the long historic success
of metformin treatment, its effects on endothelium-dependent responses remain to be examined. It was recently reported that metformin improved vascular dysfunction and increased EDH-mediated relaxations in diabetic rats, and that α₁-subunit of AMPK is involved in the beneficial effects of exercise and prevention of diabetic vascular dysfunction in mice. Although we have recently demonstrated the involvement of eAMPK α₁-α₁-α₁-α₁ mice but enhanced the endothelium-dependent compensatory responses mediated by NO and prostacyclin. The present findings could provide clues to develop new therapeutic strategy for the treatment and the prevention of metabolic cardiovascular diseases with a special reference to AMPK.

Limitations
Several limitations should be mentioned for the present study. First, intracellular signaling pathways linking AMPKα₁α₁ and EDH remain to be fully elucidated. In mesenteric and coronary arteries, the major EDHF remains to be elucidated. The present study suggests that mechanisms are involved to maintain glucose tolerance and lipid profiles were fairly preserved in eAMPK α₁-α₁-α₁-α₁-α₁ mice. It remains to be examined whether some other unknown compensatory mechanisms are involved to maintain glucose tolerance and lipid profiles in those mice.

Clinical Implications
As discussed above, AMPK serves as an important metabolic regulator. Activation of AMPK in whole body is known to exert beneficial effects in obesity, metabolic syndrome, and diabetes mellitus associated with hypertension. However, the long-term effects of systemic activation of AMPK remains controversial, and tissue-specific role of endothelial AMPK remains to be elucidated. The present study suggests that genetically induced dysfunction of endothelial AMPK causes EDH impairment with resultant hypertension in mice, suggesting the involvement of dysfunction of endothelial AMPK in the pathogenesis of hypertension and impaired coronary flow responses in patients with metabolic disorder. In conclusions, we were able to demonstrate that α₁-α₁-α₁-α₁-α₁ of eAMPK substantially mediates EDH responses of resistance arteries and thus regulates blood pressure and coronary flow responses in mice in vivo, demonstrating the novel role of eAMPK in cardiovascular homeostasis.

Acknowledgments
We thank Akemi Saito for excellent technical assistance and all members of our laboratory for their contributions to the work. We thank Dr. Viollet, Cochin Institute (Paris, France), for providing us with AMP-activated protein kinase floxed mice.

Sources of Funding
This work was supported, in part, by Japanese Scientific Promotion Society grant and a Grant-in-Aid for Scientific Research on Innovative Areas (Signaling Functions of Reactive Oxygen Species), a Grant-in-Aid for Tohoku University Global COE for Conquest of Signal Transduction Diseases with Network Medicine, and Grants-in-Aid for Scientific Research, all of which are from the Ministry of Education, Culture, Sports, Science, and Technology, Tokyo, Japan.

Disclosures
None.

References


---

**Significance**

Vascular endothelial dysfunction plays a critical role in the pathogenesis of metabolic syndrome, where AMP-activated protein kinase (AMPK) plays important roles as a metabolic sensor. However, because the systemic AMPK double knockout mice are embryonic lethal, the specific role of endothelial AMPK (eAMPK) remains to be elucidated. To address this important issue, we newly generated endothelium-specific eAMPK-knockout mice and examined the roles of eAMPK in endothelium-dependent responses. In the present study, we were able to demonstrate that eAMPKα1 is the main upstream enzyme that mediates endothelium-dependent hyperpolarization in resistance arteries, including the coronary and mesenteric arteries for blood pressure regulation and coronary flow responses, respectively, demonstrating the novel role of eAMPK in cardiovascular homeostasis.
Endothelial AMP-Activated Protein Kinase Regulates Blood Pressure and Coronary Flow Responses Through Hyperpolarization Mechanism in Mice
Budbazar Enkhjargal, Shigeo Godo, Ayuko Sawada, Nergui Suvd, Hiroki Saito, Kazuki Noda, Kimio Satoh and Hiroaki Shimokawa

Arterioscler Thromb Vasc Biol. 2014;34:1505-1513; originally published online May 22, 2014; doi: 10.1161/ATVBAHA.114.303735

Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/34/7/1505

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2014/05/22/ATVBAHA.114.303735.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
Materials and Methods

Animals
This study was reviewed and approved by the Committee on Ethics of Animal Experiments of Tohoku University. We generated eAMPKα1<sup>−/−</sup>α2<sup>+/+</sup>, eAMPKα1<sup>+/+</sup>α2<sup>−/−</sup> and eAMPKα1<sup>−/−</sup>α2<sup>−/−</sup> mice by crossing AMPK floxed (f) mice<sup>1</sup> with Tie2-Cre mice<sup>2</sup> on a C57BL/6 background of both mice. Each littermate was used as controls (control<sub>α1</sub>f/f α2<sup>+/+</sup>, control<sub>α1</sub><sup>+/+</sup>α2<sup>f/f</sup> and control<sub>α1</sub>f/f α2<sup>f/f</sup>, respectively). The genotype of the mice was confirmed by polymerase chain reaction using primers specific for the AMPKα1 gene (5`-TATTGCTGCAATTAGGCTAC-3` and 5`-GACCTGACAGAATAGGATATGCCCAACCTC-3`), the AMPKα2 gene (5`-GCTTAGCACGTTACCCTGGATGG-3` and 5`-GTTATCAGCCCAACTAATTACAC-3`) and the Tie2-Cre transgene (5`-GCGGTCTGGCAGTAAAAACTATC-3` and 5`-GTGAAACAGCATTGCTGTCACTT-3`). DNAs were amplified 35 cycles at 94°C for 30 sec, 58°C for 40 sec and 72°C for 50 sec in a thermal cycler. Tie2-Cre mice were purchased from Jackson Laboratory. Heterozygous mice backcrossed 4-6 times to fix genotypes and all experiments were performed with generation F4-6. In the present study, we only used male mice. They were maintained on 23±2°C, 50±10% relative humidity, 12/12 hour light/dark cycle, 13-15 cycles of air exchange and received standard rodent diet (CE-II, Labo MR Stock, Nusan Corporation, Yokohama, Japan) and water ad libitum. Male eAMPK-KO mice and each littermate mouse, 16-20 weeks old, were used in the present study.

Telemetry experiments in vivo
The mice were anesthetized with 1.5-2% escaim in 190-200 mL of O<sub>2</sub> per minute with postoperative analgesia by carprofen 5 mg/kg, which carprofen was once administered subcutaneously. The sufficiency of anesthesia was determined by the respiration rate and the absence of the blink and paw pinch reflex. At week 3, a telemetry probe catheter (TA11PA-C10, Data Science International, St. Paul, MN, USA) was implanted into the aortic arch through the left carotid artery. All surgeries were performed using sterile technique and after the operation, the animals were treated with cefazolin 100 mg/kg for 3 days. They were housed individually for 1 week on top of the telemetry receivers to allow environmental adaptation before telemetry recording.

Organ chamber experiments
The mice were euthanized by intraperitoneal pentobarbital (50 mg/kg) anesthesia. The aorta and the first branches of mesenteric arteries were isolated and immersed in ice cold Krebs-Henseleit buffer (KHB) bubbled with 95% O<sub>2</sub> and 5% CO<sub>2</sub>. The aorta and mesenteric arteries (200-250 μm in diameter) were cut into 0.9-1.0 mm long segments and threaded onto 40 μm steel and 30 μm tungsten wires, respectively. Then, the aorta and mesenteric arteries were loaded with 7-7.5 and 3-3.5 mN resting tension, respectively, which are optimal tension that induces a constant contractile response to 60 mmol/L KCl, as previously demonstrated.<sup>3</sup> Each segment was
mounted in an organ chamber of isometric myograph (620M, Danish Myo Technology, Aarhus, Denmark) and was equilibrated for 1 hour. Experiments were monitored by a computer-based analysis system in Mac-Lab and Chart 7.0 software. After 1 hour equilibration, the preparations were stimulated with 60 mmol/L KCl solution, in which part of NaCl had been replaced by an equimolar amount of KCl, containing (mmol/L) NaCl 22.6, KCl 98.8, NaHCO₃ 25, MgSO₄ 1.2, KH₂PO₄ 1.2, CaCl₂ 1.2, glucose 10 at pH 7.4 and 37°C. After washout and 30 min recovery, the preparations were exposed to agonists and cumulative doses were added to organ chambers at 2-3 min intervals.

**Electrophysiological experiments**

The rings of small mesenteric arteries were placed in experimental chambers perfused with 37 °C KHB containing indomethacin (10 µmol/L) and L-NNA (100 µmol/L) bubbled with 95% O₂ and 5% CO₂. A fine glass capillary microelectrode was impaled into the smooth muscle from the adventitial side of mesenterial arteries, and changes in membrane potential were continuously recorded as previously described.⁴,⁵

**Langendorff experiments**

After 10 min heparinization (500 units IP), the mice were anesthetized with 50 mg/kg pentobarbital sodium injected intraperitoneally and thoracotomy was performed and the lungs with the trachea were removed, and the hearts were isolated rapidly from the animals. The hearts were then quickly excised and placed in ice-cold KHB including 0.5 mmol/L EDTA to arrest cardiac contraction. After all extracardiac tissues were removed, the aorta was carefully tied to an aortic cannula with a 21-gauge blunted needle within 5 min. The heart was perfused retrogradely by constant 1.8-2 ml/min flow at a constant pressure of 80 mmHg with warm KHB and was allowed to beat once more spontaneously. After the stabilization period, the heart was paced at 400 pulses per minute constant rate throughout the experiments. The heart was surrounded by a water-jacketed organ bath for maintenance of constant temperature for 30 min. The buffer was pre-filtered to particle size of <0.11 µm and bubbled continuously with 95% O₂ and 5% CO₂ at 37 °C. Air bubble trap (Physio-Tech Co. Ltd., Tokyo, Japan) and 0.45 µm pore filter (Merck Millipore Ltd., Darmstadt, Germany) were equipped in forward of blunted needle to avoid air embolization. Coronary flow was continuously measured using flowmeter (FLSC-01, Primetech. Corp Ltd., Tokyo, Japan) placed in the aortic perfusion line. The flowmeter was monitored by a computer-based analysis system in Mac-Lab and Chart 7.0 software.⁵ All chemicals were applied by infusion method with accurate final concentration.

**Hydralazine and metformin treatment**

Twelve week-old controlα₁<sup>−/−</sup>α₂<sup>−/−</sup> and eAMPK<sub>α₁<sup>−/−</sup>α₂<sup>−/−</sup></sub> mice were treated with hydralazine (0.12 mg/L) or metformin (2 mg/mL) in drinking water for 1 month. Telemetry was implanted at week 3 and blood pressure was measured at week 4.
Immunofluorescence staining
The aorta, mesentery and heart were washed in PBS containing sucrose, and the samples were embedded in OCT compound and quickly frozen. The tissues were cut into 10-μm thick slices. Anti-CD31 (BD Pharmingen) and anti-AMPK (ab80039, Abcam) antibodies were applied at a dilution of 1:1000 and incubated overnight at 4º C, followed by incubation with secondary antibodies 1 hour at room temperature. Slides were viewed in ZEN software with a fluorescence microscopy (LSM 780, Carl Zeiss, Oberkochen, Germany).

Glucose tolerance tests
eAMPKα1-/α2-/- and control α1-/--α2-/-- mice were fasted overnight for the glucose tolerance test. Glucose (1 g/kg body weight) was injected intraperitoneally and blood was collected from the tail vein at different time points. Blood glucose test was carried out using Glutest-ace (Sanwa Kagaku Kenkyusho Co., Ltd, Nagoya, Japan).

Blood and serum analysis
Blood samples were collected from the right ventricle by direct punctuation and 300-400 μl of the sample were mixed in 3-4 μL of 0.5 mmol/L EDTA. Blood cell counts were determined using a multi-automatic blood cell counter for animals with mouse species program (MICROS LC-152, Horiba, France). The remaining blood samples were put 15 min in room temperature and collected the serum by centrifugation (3000 rpm, 15 min, 4 ºC). Serum levels of lipids were analyzed with high-performance liquid chromatography system by Skylight Biotech (Tokyo, Japan).

Histological Analysis
Histological analyses were performed in mice at 16-20 weeks old. The whole mice heart was fixed with 10% buffered formalin for 24-48 hours, then embedded in paraffin wax, and was cut into 3-μm-thick sections that were perpendicular to the long axis of the LV. The sections were then stained with hematoxylin-eosin according to standard histological procedures. For each animal, 20 points were measured for the wall thickness of the LV and the average was calculated. A computer-aided manipulator program (KS-Analyzer v 2.10, Keyence Corp., Osaka, Japan) was used for the analysis.

Chemicals and reagents
Nω-nitro-L-arginine (L-NNA), indomethacin, apamin, (R)-(−)-phenylephrine hydrochloride (PE), acetylcholine (ACh), bradykinin (BK), hydralazine hydrochloride were purchased from Sigma-Aldrich (St. Louis, MO, USA), metformin from LKT laboratories, Inc. (St. Paul, MN, USA), and charybdotoxin from Peptide Institute, Inc. (Osaka, Japan). Indomethacin was dissolved in 10 mmol/L Na2CO3. Other drugs dissolved in distilled water were stocked as 1-10 mmol/L solutions. All chemicals and materials of the highest grade available commercially were used at the following final concentrations: PE (1 μmol/L), BK (1 μmol/L), L-NNA (100 μmol/L), a non-
selective NOS inhibitor; indomethacin (10 μmol/L), apamin (100 nmol/L), a small-conductance K$_{Ca}$ channel (SK$_{Ca}$) blocker; charybdotoxin (100 nmol/L), an intermediate (IK$_{Ca}$)- and a large- (BK$_{Ca}$) conductance K$_{Ca}$ blocker. PE was used for precontraction of the arteries.

**Statistical analysis.**

Data analysis was performed by using IBM SPSS Statistics software version 21 (IBM, Armonk, New York, USA). Data are shown as mean ± SEM. Dose-response curves were analyzed by 2-way ANOVA followed by LSD post-hoc test for multiple comparisons. All variables were analyzed by independent paired t-test. $P<0.05$ was considered to be statistically significant.
References


Supplemental Materials

Legends to Supplemental Figures

Supplemental Figure I. Characterization of eAMPK-KO mice
A. Genotypes of background mice including AMPK floxed (f), Tie2-Cre (Tie2), heterozeguos (h) mice, and control alf alf (1), eAMPKalf a2−/− (2), control alf a2+/+ (3), eAMPKalf a2−/− (4), control alf a2+/+ (5), eAMPKalf a2−/− (6) mice. B. Glucose tolerance test (GTT) in the eAMPK alf a2−/− mice, and control alf a2−/− and control alf a2−/− mice (n=5 each). Results are expressed as mean ± SEM.

Supplemental Figure II. Elevated systolic and diastolic blood pressure in eAMPK-KO mice
Telemetric blood pressure monitoring in (A) eAMPKalf a2−/− vs. control alf a2−/−, (B) eAMPKalf a2+/+ vs. control alf a2+/+, and (C) eAMPKalf a2−/− vs. control alf a2−/− (n=5-6 each). Data are presented as SBP (left) and DBP (right) during 24 hours recording. Results are expressed as mean ± SEM. *P<0.05 vs. control.

Supplemental Figure III. Heart rate in eAMPK-KO mice
Telemetric heart rate monitoring in (A) eAMPKalf a2−/− vs. control alf a2−/−, (B) eAMPKalf a2+/+ vs. control alf a2+/+, and (C) eAMPKalf a2−/− vs. control alf a2−/− (n=5-6 each). Data are presented as heart rate during 24 hours recording (left) and time-averaged heart rate (right). Results are expressed as mean ± SEM.

Supplemental Figure IV. Hydralazine and metformin failed to ameliorate LV hypertrophy in eAMPKalf a2−/− mice
Telemetric blood pressure monitoring in eAMPKalf a2−/−, hydralazine and metformin -treated eAMPKalf a2−/− and control alf a2−/− mice. A. Mean arterial pressure (MAP) during 24 hours recording (left) and time-averaged MAP (right). B. Systolic (SBP), diastolic (DBP) blood pressure during 24 hours recording (left) and time-averaged SBP and DBP (right). C. Heart rate during 24 hours recording (left) and time-averaged heart rate (right). D. Histologic analysis of LV hypertrophy. (n=4-5 each). Results are expressed as mean ± SEM. *P<0.05 vs. controlalf a2−/−. †P<0.05 vs. eAMPKalf a2−/− mice.

Supplemental Figure V. Contracting responses to KCl
Standard contractile responses to 60 mmol/L of KCl (n=10 each). Results are expressed as mean ± SEM.
Supplemental Figure VI. Endothelium-dependent relaxations of the aorta of eAMPK-KO and control mice.

Endothelium-dependent relaxations to acetylcholine (ACh) in (A) eAMPK_{α1^{-/-}α2^{-/-}} vs. control_{α1^{-/-}α2^{-/-}}, (B) eAMPK_{α1^{-/-}α2^{+/+}} vs. control_{α1^{-/-}α2^{+/+}} and (C) eAMPK_{α1^{+/+}α2^{-/-}} vs. control_{α1^{+/+}α2^{-/-}} mice (n=7~10 each) in the absence (circle) and the presence of indomethacin (square, Indo), indomethacin plus N^{o}-nitro-L-arginine (triangle, L-NNA), and indomethacin, L-NNA plus charybdotoxin (CTx) and apamin (lozenge, Apm). Data are presented as dose-dependent responses (left) and area under the curve (right). Results are expressed as mean ± SEM.

Supplemental Figure VII. Endothelium-dependent relaxations in hydralazine-treated mice

Endothelium-dependent responses to acetylcholine (ACh) of the aorta (A) and mesenteric arteries (B) after hydralazine treatment in eAMPK_{α1^{-/-}α2^{-/-}} (n=7 each) vs. control_{α1^{-/-}α2^{-/-}} mice (n=4) in the absence (circle) and the presence of indomethacin (square, Indo), indomethacin plus N^{o}-nitro-L-arginine (triangle, L-NNA), and indomethacin, L-NNA plus charybdotoxin (CTx) and apamin (lozenge, Apm). Data are presented as dose-dependent responses (left) and area under the curve (right). Results are expressed as mean ± SEM. **P<0.01.

Supplemental Figure VIII. Endothelium-dependent relaxations in metformin-treated mice

Endothelium-dependent responses to acetylcholine of the aorta (Ao) and mesenteric arteries (B) after metformin treatment in eAMPK_{α1^{-/-}α2^{-/-}} and control_{α1^{-/-}α2^{-/-}} mice (n=6 each) in the absence (circle) and the presence of indomethacin (square, Indo), indomethacin plus N^{o}-nitro-L-arginine (triangle, L-NNA), and indomethacin, L-NNA plus charybdotoxin (CTx) and apamin (lozenge, Apm). Data are presented as dose-dependent responses (left) and area under the curve (right). Results are expressed as mean ± SEM. **P<0.01.

Supplemental Figure IX. Endothelium-independent relaxations to sodium nitroprusside

Endothelium-independent relaxations to sodium nitroprusside (SNP) in (A) eAMPK_{α1^{-/-}α2^{-/-}} vs. control_{α1^{-/-}α2^{-/-}}, (B) eAMPK_{α1^{-/-}α2^{+/+}} vs. control_{α1^{-/-}α2^{+/+}} and (C) eAMPK_{α1^{+/+}α2^{-/-}} vs. control_{α1^{+/+}α2^{-/-}} mice (n=10 each). Results are expressed as mean ± SEM. *P<0.05 vs. control.

Supplemental Figure X. Endothelium-independent relaxations to NS-1619

Endothelium-independent relaxations to NS-1619 in (A) eAMPK_{α1^{-/-}α2^{-/-}} vs. control_{α1^{-/-}α2^{-/-}}, (B) eAMPK_{α1^{-/-}α2^{+/+}} vs. control_{α1^{-/-}α2^{+/+}} and (C) eAMPK_{α1^{+/+}α2^{-/-}} vs. control_{α1^{+/+}α2^{-/-}} mice (n=4-5 each). Results are expressed as mean ± SEM.
Supplemental Figure XI. Endothelium-independent relaxations to exogenous H₂O₂
Endothelium-independent relaxations to exogenous H₂O₂ in (A) eAMPKα₁⁻/⁻α₂⁻/⁻ vs. controlα₁²/², (B) eAMPKα₁⁻/⁺α₂⁻/⁺ vs. controlα₁²/² and (C) eAMPKα₁⁺/⁺α₂⁻/⁻ vs. controlα₁²/² mice (n=4-5 each). Results are expressed as mean ± SEM.

Supplemental Figure XII. Effects of hydralazine treatment on endothelium-independent relaxations
No effects of hydralazine treatment were noted on endothelium-independent relaxations to sodium nitroprusside (SNP) (A), NS-1619 (B), and exogenous H₂O₂ (C) in control and eAMPKα₁⁻/⁻α₂⁻/⁻ mice (n=7 each). Results are expressed as mean ± SEM.

Supplemental Figure XIII. Effects of hydralazine treatment on endothelium-independent relaxations
No effects of hydralazine treatment were noted on endothelium-independent relaxations to sodium nitroprusside (SNP) (A), NS-1619 (B), and exogenous H₂O₂ (C) in control (n=6) and eAMPKα₁⁻/⁺α₂⁻/⁻ mice (n=7). Results are expressed as mean ± SEM.
Supplemental Figure 1

A

1. Control\(_{\alpha_1^{+/-} \alpha_2^{+/-}}\) 3. Control\(_{\alpha_1^{+/-} \alpha_2^{+/+}}\)
2. eAMPK\(_{\alpha_1^{+/-} \alpha_2^{+/-}}\) 4. eAMPK\(_{\alpha_1^{+/-} \alpha_2^{+/+}}\)
5. Control\(_{\alpha_1^{+/-} \alpha_2^{+/-}}\) 6. eAMPK\(_{\alpha_1^{+/-} \alpha_2^{+/-}}\)

B

Glucose (mg/dL)

<table>
<thead>
<tr>
<th>Time (min)</th>
<th>Control(_{\alpha_1^{+/-} \alpha_2^{+/-}})</th>
<th>eAMPK(_{\alpha_1^{+/-} \alpha_2^{+/-}})</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>15</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>30</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>60</td>
<td>150</td>
<td>150</td>
</tr>
<tr>
<td>120</td>
<td>50</td>
<td>50</td>
</tr>
</tbody>
</table>

GTT-AUC

<table>
<thead>
<tr>
<th>GTT-AUC</th>
</tr>
</thead>
<tbody>
<tr>
<td>20000</td>
</tr>
</tbody>
</table>
Supplemental Figure II

A

- Control α_{1α}^{-/-} α_{2β}^{-/-}
- eAMPK α_{1α}^{++} α_{2β}^{++}

SBP (mmHg)

Day
Night

DBP (mmHg)

B

- Control α_{1α}^{++} α_{2β}^{-/-}
- eAMPK α_{1α}^{++} α_{2β}^{++}

C

- Control α_{1α}^{++} α_{2β}^{++}
- eAMPK α_{1α}^{−/+} α_{2β}^{−/−}

SBP (mmHg)

Day
Night

DBP (mmHg)
Supplemental Figure III

A

B

C
Supplemental Figure IV

A

MAP (mmHg)

Control $\alpha_1^{+/+}, \alpha_2^{+/+}$

eAMPK $\alpha_1^{-/-}, \alpha_2^{-/-}$

eAMPK $\alpha_1^{-/-}, \alpha_2^{-/-}$ plus hydralazine

eAMPK $\alpha_1^{-/-}, \alpha_2^{-/-}$ plus metformin

Day

Night

Time (h)

B

SBP (mmHg)

DBP (mmHg)

BP (mmHg)

Systolic

Diastolic

Day

Night

Day

Night

Day

Night

Time (h)

C

Heart rate (b/min)

Day

Night

Time (h)

D

Wall thickness (mm)

Hydralazine: - - + -

Metformin: - - + -

Wall thickness (mm)

Day

Night

Time (h)
Supplemental Figure V

Aorta

MA

Control_{α_{1}^{+}/α_{2}^{+}}
Control_{α_{1}^{+}/α_{2}^{+}}
Control_{α_{1}^{+}/α_{2}^{+}}
eAMPK_{α_{1}^{+}/α_{2}^{+}}
eAMPK_{α_{1}^{+}/α_{2}^{+}}
eAMPK_{α_{1}^{+}/α_{2}^{+}}

Contraction (mN)

KCl (60 mmol/L)
Supplemental Figure VI

A

Control_{\alpha_1^{+/+} \alpha_2^{-/-}}

NO

Relaxation (%)

ACh (-log mol/L)

Control_{\alpha_1^{++} \alpha_2^{--}}

Relaxation (%)

ACh (-log mol/L)

Control_{\alpha_1^{-/-} \alpha_2^{+-}}

Relaxation (%)

ACh (-log mol/L)

B

Control_{\alpha_1^{++} \alpha_2^{-/-}}

eAMPK_{\alpha_1^{-/-} \alpha_2^{+-}}

NO

Relaxation (%)

ACh (-log mol/L)

Relaxation (%)

ACh (-log mol/L)

C

eAMPK_{\alpha_1^{+-} \alpha_2^{-/-}}

NO

Relaxation (%)

ACh (-log mol/L)

Relaxation (%)

ACh (-log mol/L)
Supplemental Figure VII

A. Ao

B. MA
Supplemental Figure VIII

A. Ao

B. MA
Supplemental Figure IX

Aorta

MA

A

B

C

Relaxation (%)

SNP (-log mol/L)

Relaxation (%)

SNP (-log mol/L)

Relaxation (%)

SNP (-log mol/L)
Supplemental Figure X

A

**Aorta**

- Control\textsubscript{\textalpha\textbeta}\textsubscript{1\textalpha\textbeta}\textsubscript{2\textalpha\textbeta}
- Control\textsubscript{\textalpha\textbeta+\textalpha\textbeta-\textalpha\textbeta-}
- Control\textsubscript{\textalpha\textbeta-\textalpha\textbeta+\textalpha\textbeta-}
- eAMPK\textsubscript{\textalpha\textbeta-\textalpha\textbeta-\textalpha\textbeta-}
- eAMPK\textsubscript{\textalpha\textbeta+\textalpha\textbeta-\textalpha\textbeta-}

**Relaxation (%)**

**NS-1619 (log mol/L)**

B

**MA**

- Control\textsubscript{\textalpha\textbeta}\textsubscript{1\textalpha\textbeta}\textsubscript{2\textalpha\textbeta}
- Control\textsubscript{\textalpha\textbeta+\textalpha\textbeta-\textalpha\textbeta-}
- Control\textsubscript{\textalpha\textbeta-\textalpha\textbeta+\textalpha\textbeta-}
- eAMPK\textsubscript{\textalpha\textbeta-\textalpha\textbeta-\textalpha\textbeta-}
- eAMPK\textsubscript{\textalpha\textbeta+\textalpha\textbeta-\textalpha\textbeta-}

**Relaxation (%)**

**NS-1619 (log mol/L)**

C

**Relaxation (%)**

**NS-1619 (log mol/L)**
Supplemental Figure XII

Aorta

**A**

- **Control**
- **eAMPK**

- SNP (\(-\log \text{ mol/L}\))
- Relaxation (%)

**B**

- NS-1619 (\(-\log \text{ mol/L}\))
- Relaxation (%)

**C**

- \(\text{H}_2\text{O}_2\) (\(-\log \text{ mol/L}\))
- Relaxation (%)

Legend:
- Open circle: Control
- Filled circle: eAMPK
Supplemental Table I. Characteristics of eAMPK-KO and control mice

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control\textsubscript{al} \textsuperscript{ef} \textsubscript{a}\textsubscript{1} \textsubscript{a}\textsubscript{2}</th>
<th>eAMPK\textsubscript{al} \textsuperscript{+/1} \textsubscript{a}\textsubscript{1} \textsubscript{a}\textsubscript{2}</th>
<th>Control\textsubscript{al} \textsuperscript{+/+} \textsubscript{a}\textsubscript{1} \textsubscript{a}\textsubscript{2}</th>
<th>eAMPK\textsubscript{al} \textsuperscript{+/−} \textsubscript{a}\textsubscript{1} \textsubscript{a}\textsubscript{2}</th>
<th>Control\textsubscript{al} \textsuperscript{−/+} \textsubscript{a}\textsubscript{1} \textsubscript{a}\textsubscript{2}</th>
<th>eAMPK\textsubscript{al} \textsuperscript{−/−} \textsubscript{a}\textsubscript{1} \textsubscript{a}\textsubscript{2}</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 weeks</td>
<td>29.7 ± 0.8</td>
<td>28.2 ± 0.7</td>
<td>32.7 ± 0.5</td>
<td>31.2 ± 0.7</td>
<td>27.6 ± 0.7</td>
<td>28.0 ± 0.9</td>
</tr>
<tr>
<td>13 weeks</td>
<td>30.1 ± 0.7</td>
<td>29.6 ± 0.6</td>
<td>33.4 ± 0.7</td>
<td>30.7 ± 0.8*</td>
<td>28.8 ± 0.6</td>
<td>28.9 ± 0.9</td>
</tr>
<tr>
<td>14 weeks</td>
<td>32.8 ± 0.8</td>
<td>29.9 ± 0.5*</td>
<td>34.1 ± 0.7</td>
<td>31.5 ± 0.9**</td>
<td>29.0 ± 0.5</td>
<td>30.1 ± 0.6</td>
</tr>
<tr>
<td>15 weeks</td>
<td>32.8 ± 0.8</td>
<td>30.6 ± 0.7*</td>
<td>34.9 ± 0.6</td>
<td>32.4 ± 0.5**</td>
<td>29.1 ± 0.6</td>
<td>29.0 ± 0.7</td>
</tr>
<tr>
<td>16 weeks</td>
<td>33.3 ± 1.2</td>
<td>30.1 ± 0.7*</td>
<td>34.2 ± 0.4</td>
<td>31.3 ± 1.3**</td>
<td>29.6 ± 0.6</td>
<td>30.2 ± 0.7</td>
</tr>
<tr>
<td>17 weeks</td>
<td>34.9 ± 0.9</td>
<td>29.6 ± 1.4**</td>
<td>35.3 ± 0.8</td>
<td>31.5 ± 1.2**</td>
<td>30.7 ± 0.7</td>
<td>30.3 ± 1.0</td>
</tr>
<tr>
<td>Organs/BW (mg/g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart/BW</td>
<td>4.9 ± 0.1</td>
<td>5.4 ± 0.2*</td>
<td>4.7 ± 0.2</td>
<td>5.4 ± 0.3**</td>
<td>4.9 ± 0.1</td>
<td>5.0 ± 0.1</td>
</tr>
<tr>
<td>Lung/BW</td>
<td>5.1 ± 0.2</td>
<td>5.4 ± 0.2</td>
<td>4.8 ± 0.2</td>
<td>4.8 ± 0.2</td>
<td>4.9 ± 0.2</td>
<td>5.0 ± 0.1</td>
</tr>
<tr>
<td>Liver/BW</td>
<td>46.9 ± 1.6</td>
<td>47.6 ± 2.1</td>
<td>47.4 ± 2.4</td>
<td>46.3 ± 1.4</td>
<td>45.2 ± 1.9</td>
<td>45.3 ± 1.9</td>
</tr>
<tr>
<td>Kidney/BW</td>
<td>15.1 ± 0.3</td>
<td>14.6 ± 0.4</td>
<td>14.3 ± 0.4</td>
<td>13.5 ± 0.4</td>
<td>14.4 ± 0.4</td>
<td>14.9 ± 0.3</td>
</tr>
<tr>
<td>Visceral fat/BW (mg/g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perinephric</td>
<td>7.4 ± 1.2</td>
<td>7.4 ± 1.6</td>
<td>7.4 ± 1.4</td>
<td>6.7 ± 1.5</td>
<td>3.6 ± 0.5</td>
<td>3.4 ± 0.9</td>
</tr>
<tr>
<td>Mesenteric</td>
<td>11.2 ± 1.6</td>
<td>13.8 ± 2.4</td>
<td>9.2 ± 1.1</td>
<td>8.9 ± 1.4</td>
<td>6.4 ± 0.8</td>
<td>4.5 ± 1.5</td>
</tr>
<tr>
<td>Epididymal</td>
<td>22.3 ± 3.3</td>
<td>21.5 ± 4.0</td>
<td>21.0 ± 2.8</td>
<td>21.0 ± 3.5</td>
<td>13.6 ± 0.9</td>
<td>13.6 ± 2.4</td>
</tr>
<tr>
<td>Omentum</td>
<td>8.5 ± 0.5</td>
<td>8.8 ± 0.6</td>
<td>9.4 ± 0.7</td>
<td>9.5 ± 0.5</td>
<td>10.5 ± 0.8</td>
<td>8.8 ± 0.4</td>
</tr>
<tr>
<td>Total</td>
<td>50.7 ± 5.4</td>
<td>56.0 ± 7.5</td>
<td>46.9 ± 5.1</td>
<td>48.1 ± 7.1</td>
<td>34.1 ± 1.8</td>
<td>24.2 ± 3.7</td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WBC (x10\textsuperscript{3}/mm\textsuperscript{3})</td>
<td>2.7 ± 0.4</td>
<td>2.3 ± 0.3</td>
<td>2.5 ± 0.2</td>
<td>3.4 ± 0.5</td>
<td>2.9 ± 0.5</td>
<td>2.5 ± 0.5</td>
</tr>
<tr>
<td>RBC (x10\textsuperscript{6}/mm\textsuperscript{3})</td>
<td>9.6 ± 0.2</td>
<td>9.5 ± 0.2</td>
<td>9.6 ± 0.2</td>
<td>9.6 ± 0.3</td>
<td>9.6 ± 0.1</td>
<td>9.4 ± 0.1</td>
</tr>
<tr>
<td>HGB (g/dL)</td>
<td>13.5 ± 0.2</td>
<td>13.5 ± 0.2</td>
<td>13.5 ± 0.3</td>
<td>13.1 ± 0.6</td>
<td>13.7 ± 0.2</td>
<td>13.5 ± 0.1</td>
</tr>
<tr>
<td>HCT (%)</td>
<td>44.8 ± 0.8</td>
<td>44.7 ± 1.0</td>
<td>44.9 ± 0.8</td>
<td>44.1 ± 2.0</td>
<td>44.8 ± 0.7</td>
<td>43.6 ± 0.4</td>
</tr>
<tr>
<td>MCV (x10\textsuperscript{15}/L)</td>
<td>46.6 ± 0.2</td>
<td>47.0 ± 0.2</td>
<td>46.7 ± 0.2</td>
<td>46.1 ± 0.7</td>
<td>46.4 ± 0.3</td>
<td>46.2 ± 0.3</td>
</tr>
<tr>
<td>MCH (pg)</td>
<td>14.1 ± 0.1</td>
<td>14.2 ± 0.1</td>
<td>14.1 ± 0.1</td>
<td>13.0 ± 0.2</td>
<td>14.2 ± 0.1</td>
<td>14.3 ± 0.1</td>
</tr>
<tr>
<td>MCHC (g/dL)</td>
<td>30.2 ± 0.2</td>
<td>30.0 ± 0.6</td>
<td>30.1 ± 0.1</td>
<td>30.0 ± 0.1</td>
<td>30.7 ± 0.3</td>
<td>31.0 ± 0.2</td>
</tr>
<tr>
<td>PLT (x10\textsuperscript{3}/mm\textsuperscript{3})</td>
<td>721.8 ± 48.5</td>
<td>756.6 ± 22.9</td>
<td>744.1 ± 28.9</td>
<td>849.5 ± 62.2</td>
<td>738.9 ± 87.8</td>
<td>662.8 ± 124.7</td>
</tr>
<tr>
<td>Lipid levels (mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>62.8 ± 4.3</td>
<td>55.7 ± 2.9</td>
<td>82.7 ± 6.1</td>
<td>92.8 ± 4.6</td>
<td>67.5 ± 8.3</td>
<td>64.4 ± 5.6</td>
</tr>
<tr>
<td>CM</td>
<td>0.20 ± 0.06</td>
<td>0.24 ± 0.05</td>
<td>0.56 ± 0.23</td>
<td>0.46 ± 0.06</td>
<td>0.30 ± 0.08</td>
<td>0.25 ± 0.11</td>
</tr>
<tr>
<td>VLDL</td>
<td>4.2 ± 0.7</td>
<td>4.0 ± 1.0</td>
<td>6.6 ± 1.2</td>
<td>6.7 ± 0.8</td>
<td>3.9 ± 1.9</td>
<td>3.4 ± 1.6</td>
</tr>
<tr>
<td>LDL</td>
<td>6.4 ± 1.0</td>
<td>5.1 ± 0.8</td>
<td>11.6 ± 1.8</td>
<td>10.0 ± 1.1</td>
<td>4.8 ± 1.1</td>
<td>4.7 ± 1.0</td>
</tr>
<tr>
<td>HDL</td>
<td>52.0 ± 3.1</td>
<td>46.3 ± 2.7</td>
<td>63.9 ± 5.6</td>
<td>75.6 ± 4.5</td>
<td>58.5 ± 8.6</td>
<td>56.2 ± 5.2</td>
</tr>
<tr>
<td>TG</td>
<td>51.2 ± 8.8</td>
<td>42.8 ± 9.2</td>
<td>76.3 ± 18.9</td>
<td>79.9 ± 8.1</td>
<td>40.0 ± 14.4</td>
<td>38.0 ± 25.3</td>
</tr>
</tbody>
</table>
Results are expressed as mean ± SEM. BW, body weight; WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; PLT, platelet; CM, chylomicrons; VLDL, very-low-density lipoprotein; LDL, low-density lipoprotein; HDL, high-density lipoprotein; TG, triglycerides. Controlα1effα2eff, controlα1effα2+/+, and controlα1+/+α2eff littermate AMPKα1α2 subunits-, AMPKα1 subunit-, and AMPKα2 subunit-floxed mice, respectively. eAMPKα1−/−α2−/−, eAMPKα1+/−α2−/−, and eAMPKα1+/+α2−/−, endothelial AMPKα1α2 subunits-, AMPKα1 subunit-, and AMPKα2 subunits-knockout mice, respectively. n= 7-10 in each group. *P<0.05, **P<0.01, ***P<0.001 vs. control.
Supplemental Table II. Effects of hydralazine and metformin treatments on the male eAMPK\(_{\alpha_1-\alpha_2^{-/-}}\) and control mice.

<table>
<thead>
<tr>
<th>Groups</th>
<th>Control(_{\alpha_1^{f/f}\alpha_2^{f/f}}) +hydralazine</th>
<th>eAMPK(_{\alpha_1^{-/-}\alpha_2^{-/-}}) +hydralazine</th>
<th>Control(_{\alpha_1^{f/f}\alpha_2^{f/f}}) +metformin</th>
<th>eAMPK(_{\alpha_1^{-/-}\alpha_2^{-/-}}) +metformin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16 weeks</td>
<td>33.9 ± 1.3</td>
<td>32.6 ± 0.4</td>
<td>33.0 ± 0.6</td>
<td>29.7 ± 1.1*</td>
</tr>
<tr>
<td>17 weeks</td>
<td>34.1 ± 0.9</td>
<td>33.7 ± 0.6</td>
<td>33.3 ± 0.8</td>
<td>30.6 ± 1.1</td>
</tr>
<tr>
<td>18 weeks</td>
<td>34.1 ± 0.6</td>
<td>34.2 ± 0.7</td>
<td>32.9 ± 0.8</td>
<td>30.3 ± 1.0</td>
</tr>
<tr>
<td>Organs/BW (mg/g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart/BW</td>
<td>5.6 ± 0.4</td>
<td>6.0 ± 0.1*</td>
<td>5.1 ± 0.1</td>
<td>6.0 ± 0.2*</td>
</tr>
<tr>
<td>Lung/BW</td>
<td>5.7 ± 0.2</td>
<td>6.7 ± 0.6*</td>
<td>5.4 ± 0.1</td>
<td>5.0 ± 0.1</td>
</tr>
<tr>
<td>Liver/BW</td>
<td>58.5 ± 5.7</td>
<td>56.1 ± 1.6</td>
<td>57.3 ± 2.0</td>
<td>56.5 ± 1.4</td>
</tr>
<tr>
<td>Kidney/BW</td>
<td>13.2 ± 0.8</td>
<td>13.7 ± 0.3</td>
<td>13.3 ± 0.3</td>
<td>13.5 ± 0.5</td>
</tr>
<tr>
<td>Visceral fat/BW (mg/g)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perinephric</td>
<td>2.4 ± 0.6</td>
<td>2.0 ± 0.3</td>
<td>3.3 ± 1.5</td>
<td>2.9 ± 0.9</td>
</tr>
<tr>
<td>Mesenteric</td>
<td>8.1 ± 1.5</td>
<td>6.5 ± 0.9</td>
<td>8.3 ± 1.4</td>
<td>9.3 ± 2.0</td>
</tr>
<tr>
<td>Epididymal</td>
<td>13.3 ± 2.5</td>
<td>11.4 ± 1.6</td>
<td>13.3 ± 3.3</td>
<td>11.7 ± 1.4</td>
</tr>
<tr>
<td>Omentum</td>
<td>13.1 ± 1.2</td>
<td>11.6 ± 0.4</td>
<td>11.7 ± 0.5</td>
<td>11.2 ± 1.1</td>
</tr>
<tr>
<td>Total</td>
<td>36.8 ± 4.2</td>
<td>31.4 ± 2.5</td>
<td>36.9 ± 6.1</td>
<td>35.1 ± 3.9</td>
</tr>
</tbody>
</table>

Results are expressed as mean ± SEM. BW, body weight; control\(_{\alpha_1^{f/f}\alpha_2^{f/f}}\), littermate AMPK\(_{\alpha_1\alpha_2}\) subunits floxed mice (n=4, plus hydralazine; n=5, plus metformin); eAMPK\(_{\alpha_1^{-/-}\alpha_2^{-/-}}\), endothelial AMPK\(_{\alpha_1\alpha_2}\) subunits knockout mice (n= 6). *P<0.05 vs. control plus treatment.